These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 19814624)

  • 1. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years.
    Goldblatt D; Southern J; Andrews N; Ashton L; Burbidge P; Woodgate S; Pebody R; Miller E
    Clin Infect Dis; 2009 Nov; 49(9):1318-25. PubMed ID: 19814624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.
    de Roux A; Schmöle-Thoma B; Siber GR; Hackell JG; Kuhnke A; Ahlers N; Baker SA; Razmpour A; Emini EA; Fernsten PD; Gruber WC; Lockhart S; Burkhardt O; Welte T; Lode HM
    Clin Infect Dis; 2008 Apr; 46(7):1015-23. PubMed ID: 18444818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.
    Søgaard OS; Lohse N; Harboe ZB; Offersen R; Bukh AR; Davis HL; Schønheyder HC; Østergaard L
    Clin Infect Dis; 2010 Jul; 51(1):42-50. PubMed ID: 20504165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants.
    Choo S; Zhang Q; Seymour L; Akhtar S; Finn A
    J Infect Dis; 2000 Oct; 182(4):1260-3. PubMed ID: 10979930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
    Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
    Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine.
    Miiro G; Kayhty H; Watera C; Tolmie H; Whitworth JA; Gilks CF; French N
    J Infect Dis; 2005 Nov; 192(10):1801-5. PubMed ID: 16235180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.
    O'Brien KL; Swift AJ; Winkelstein JA; Santosham M; Stover B; Luddy R; Gootenberg JE; Nold JT; Eskenazi A; Snader SJ; Lederman HM
    Pediatrics; 2000 Nov; 106(5):965-72. PubMed ID: 11061761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
    Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
    Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine.
    Balmer P; Borrow R; Arkwright PD
    Vaccine; 2007 Aug; 25(34):6321-5. PubMed ID: 17629373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants.
    Choo S; Seymour L; Morris R; Quataert S; Lockhart S; Cartwright K; Finn A
    Pediatr Infect Dis J; 2000 Sep; 19(9):854-62. PubMed ID: 11001109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Neuzil KM; Nahm MH; Whitney CG; Yu O; Nelson JC; Starkovich PT; Dunstan M; Carste B; Shay DK; Baggs J; Carlone GM
    Vaccine; 2007 May; 25(20):4029-37. PubMed ID: 17391816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients.
    Kumar D; Chen MH; Wong G; Cobos I; Welsh B; Siegal D; Humar A
    Clin Infect Dis; 2008 Oct; 47(7):885-92. PubMed ID: 18715160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 ×, 2 ×, or 4 ×) in healthy subjects aged 70 years or older.
    Lode H; Schmoele-Thoma B; Gruber W; Ahlers N; Fernsten P; Baker S; Razmpour A; Siber G; Hackell J; Lockhart S; Burkhardt O; Welte T; de Roux A
    Vaccine; 2011 Jul; 29(31):4940-6. PubMed ID: 21596077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
    de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of pneumococcal vaccination of patients with cochlear implants.
    Rose M; Hey C; Kujumdshiev S; Gall V; Schubert R; Zielen S
    J Infect Dis; 2004 Aug; 190(3):551-7. PubMed ID: 15243931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.